BioVectra Builds Fermentation and Complex Chemistry Facility in Nova Scotia

May 30, 2017
BioPharm International Editors

BioVectra will open its new microbial fermentation and complex chemistry site, including the capability to handle high-potency APIs, by the end of 2017.

BioVectra, a Mallinckrodt Pharmaceuticals company and CDMO based in Canada, announced in a May 24, 2017 press release that its fourth cGMP facility will be fully operational by December 2017. The late-stage to commercial-scale microbial fermentation and complex chemistry facility is located in Windsor, Nova Scotia.

BioVectra’s $30-million investment has equipped the 50,000-ft2 facility with 40,000 L of fermentation capacity, downstream processing equipment, and new preclinical fermentation and potent chemistry suites. The new facility is an investment in BioVectra’s core development and manufacturing competencies: microbial fermentation and complex chemistries. The company provides scalable cGMP operations from 30 L to 17,000 L. BioVectra has the capability to handle the development and cGMP scale-up of high-potency APIs, handling potent substances such as antibody-drug conjugate warheads, with occupational exposure limit levels of < 20 ng/m3 (Safebridge Band 3 and 4).

The new facility increases BioVectra’s ability to partner with global pharmaceutical companies by offering dual-site risk mitigation. “This expansion helps BioVectra keep up with the growing demand for our products, while also meeting an underserved need for large-scale microbial fermentation in North America,” said Heather Delage, vice-president of Business Development. “In addition to the facility’s large-scale fermentation capability, the site also offers a complementary footprint for synthetic process development and laboratory-based activities.”

BioVectra’s three additional cGMP facilities and headquarters are located in Charlottetown, Prince Edward Island.

Source: BioVectra